Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2012

View Archived Issues

Cross-strain neutralizing malaria vaccines evaluated in preclinical study

Pathogen-specific R-type pyocin may hold promise to treat EHEC infections

Naturally occurring antiobesity agent mimics calorie restriction in patients with obesity

Phase II study investigates effects of ganetespib in subjects with breast cancer

New metabotropic glutamate mGlu5 receptor antagonists prepared by GlaxoSmithKline

Novel TNF-alpha production inhibitors presented by scientists in China

Novel tyrosine-protein kinase BTK inhibitors disclosed by Ono Pharmaceutical

Dainippon Sumitomo Pharma synthesizes new Toll-like receptor antagonists

New free fatty acid FFA2 receptor agonists/partial agonists reported by Euroscreen

New acetyl-L-carnitine salt prepared in Korea

Bayer Schering Pharma presents new protein kinase inhibitors

Interim data presented from phase I/II trial of neratinib plus capecitabine in breast cancer

Osiris reports on phase II trial of Prochymal

Generex provides update on second-generation peptide vaccine for cancer

Ikaria begins registration trial of bioabsorbable matrix for use after heart attack

SNS01-T shows synergy with lenalidomide in human cancer model

BioMarin's IND for achondroplasia therapy is active

Ampio Pharmaceuticals completes expanded enrollment in Ampion trial

Gene therapy for hemophilia B granted orphan drug status by FDA

Yakult Honsha begins phase I/II study of perifosine in Japan

Phase I/II CF-102 trials meet primary endpoints

MacuCLEAR raises funds and enters partnership for lead AMD treatment

BioMimetic Therapeutics receives response to Augment Bone Graft PMA

FDA approves label expansion for CSL Behring's Berinert

BioMimetic obtains CE mark for growth factor-enhanced matrix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...